Adult stem cell therapy for stroke - StemCyte
Latest Information Update: 29 Jul 2015
At a glance
- Originator Academia Sinica
- Developer Academia Sinica; StemCyte
- Class Stem cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stroke